Phase 1 multicenter, single-arm, open-label study assessing the safety, distribution, and dosing of Debio 1124 in patients with advanced, unresectable pulmonary and extrapulmonary small cell carcinoma
Latest Information Update: 27 Aug 2020
At a glance
- Drugs Debio-1124 (Primary)
- Indications Carcinoma; Lung cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Debiopharm
- 27 Aug 2020 New trial record
- 26 Aug 2020 According to a Debiopharm media release, first patient has been dosed.